Release of muscle α-actin into serum after intensive exercise

Purpose: To study the effects of high-level matches on serum alpha actin and other muscle damage markers in teams of rugby and handball players. Methods: Blood samples were drawn from 23 sportsmen: 13 rugby players and 10 handball players. One sample was drawn with the player at rest before the match and one immediately after the match. Immunoassays were used to determine troponin I, troponin T, LDH, and myoglobin concentrations. Western blot and densitometry were used to measure α-actin concentrations. Muscle injury was defined by a total CK value of > 500 IU/L (Rosalki method). Results: Mean pre- and post-match serum alpha-actin values were, respectively, 7.16 and 26.47 μg/ml in the handball group and 1.24 and 20.04 μg/ml in the rugby team. CPK, LDH and myoglobin but not troponin 1 levels also significantly differed between these time points. According to these results, large amounts of α-actin are released into peripheral blood immediately after intense physical effort. Possible cross-interference between skeletal and cardiac muscle damage can be discriminated by the combined use of α-actin and troponin I. Conclusion: The significant increase in alpha-actin after a high-level match may be a reliable marker for the early diagnosis and hence more effective treatment of muscle injury

Desarrollo de una herramienta basada en un soporte multimedia para el autoaprendizaje de la anatomía radiológica

La instauración del Espacio Europeo de Educación Superior nos conduce a la adopción de procesos de renovación en la metodología docente. Se deben desarrollar estrategias en las que el alumno sea protagonista de su propio aprendizaje. En nuestro ámbito enseñanza, las Ciencias de la Salud, nos enfrentamos a la necesidad de aplicar estos principios integrando conocimientos básicos y clínicos y desarrollando materiales útiles en la actividad profesional de nuestros alumnos. En este contexto, diferentes Profesores del Área de Anatomía y Embriología Humana hemos desarrollado un material docente que interesa a un conjunto de conocimientos de significada complejidad comunes a las diferentes Licenciaturas y Diplomaturas de Ciencias de la Salud. Nuestra aplicación permite el estudio individual de elementos osteológicos y la compresión de los patrones radiológicos normales. Dicho material podrá ser utilizado en procesos de enseñanza aprendizaje mediante sistemas didácticos alternativos

Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint inflammation and cartilage and bone tissue destruction. Although there exist some treatment strategies for RA, they are not completely safe and effective. Therefore, it is important to develop and test new drugs for RA that specifically target inflamed/swollen joints and simultaneously attenuate other possible damages to healthy tissues. Nanotechnology can be a good alternative to consider when envisioning precise medication for treating RA. Through the use of nanoparticles, it is possible to increase bioavailability and bioactivity of therapeutics and enable selective targeting to damaged joints. Herein, recent studies using nanoparticles for the treatment of RA, namely with liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been reviewed. These therapeutic strategies have shown great promise in improving the treatment over that by traditional drugs. The results of these studies confirm that feasibility of the use of nanoparticles is mainly due to their biocompatibility, low toxicity, controlled release, and selective drug delivery to inflamed tissues in animal RA models. Therefore, it is possible to claim that nanotechnology will, in the near future, play a crucial role in advanced treatments and patient-specific therapies for human diseases such as RA.Financial support under the ARTICULATE project (No. QREN-13/SI/2011-23189). This study was also funded by the Portuguese Foundation for Science and Technology (FCT) project OsteoCart (No. PTDC/CTM-BPC/115977/2009), as well as the European Union’s FP7 Programme under grant agreement no REGPOT-CT2012-316331-POLARIS. The FCT distinction attributed to J. M. O. under the Investigator FCT program (No. IF/00423/2012) is also greatly acknowledged. C. G. also wished to acknowledge FCT for supporting her research (No. SFRH/BPD/94277/2013)info:eu-repo/semantics/publishedVersio

ojo el mesh carcinogenesis por lo que sea esta mal emn el repo y pone cocarcinogenesis, lo corrijo en este item pero hay que ver lo que es

Journal Article;Oncogenic microRNAs (miRs) have emerged as diagnostic biomarkers and novel molecular targets for anti-cancer drug therapies. Real-time quantitative PCR (qPCR) is one of the most powerful techniques for analyzing miRs; however, the use of unsuitable normalizers might bias the results. Tumour heterogeneity makes even more difficult the selection of an adequate endogenous normalizer control. Here, we have evaluated five potential referenced small RNAs (U6, rRNA5s, SNORD44, SNORD24 and hsa-miR-24c-3p) using RedFinder algorisms to perform a stability expression analysis in i) normal colon cells, ii) colon and breast cancer cell lines and iii) cancer stem-like cell subpopulations. We identified SNORD44 as a suitable housekeeping gene for qPCR analysis comparing normal and cancer cells. However, this small nucleolar RNA was not a useful normalizer for cancer stem-like cell subpopulations versus subpopulations without stemness properties. In addition, we show for the first time that hsa-miR-24c-3p is the most stable normalizer for comparing these two subpopulations. Also, we have identified by bioinformatic and qPCR analysis, different miR expression patterns in colon cancer versus non tumour cells using the previously selected suitable normalizers. Our results emphasize the importance of select suitable normalizers to ensure the robustness and reliability of qPCR data for analyzing miR expression.This work was supported in part by grants from the Fundación Pública Andaluza Progreso y Salud, Consejería de Salud Junta de Andalucía in collaboration with JANNSSEN CILAG,S.A. (project numbers PI-0533-2014, PI-0441-2014), from the Ministerio de Economía y Competitividad (MINECO, FEDER funds, grant number MAT2015-62644-C2-2-R) from the Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds, project DTS15/00174) and from the Chair “Doctors Galera-Requena in cancer stem cell research”.Ye